EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 122 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival October 3, 2018 Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... May 10, 2023 Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... March 25, 2021 FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... September 15, 2023 Load more HOT NEWS When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in...
